Health Catalyst, Inc. (NASDAQ:HCAT) CFO Jason Alger Sells 19,599 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) CFO Jason Alger sold 19,599 shares of Health Catalyst stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $163,063.68. Following the completion of the sale, the chief financial officer now directly owns 86,712 shares in the company, valued at approximately $721,443.84. The trade was a 18.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT traded up $0.03 during midday trading on Tuesday, hitting $8.37. 393,567 shares of the stock were exchanged, compared to its average volume of 564,733. The stock has a market cap of $509.30 million, a P/E ratio of -6.20 and a beta of 1.31. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a 50 day moving average price of $8.13 and a 200-day moving average price of $7.39. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter in the prior year, the company earned ($0.22) earnings per share. The firm’s revenue was up 3.5% compared to the same quarter last year. On average, research analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Institutional Trading of Health Catalyst

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC purchased a new position in Health Catalyst during the third quarter worth about $34,000. Nisa Investment Advisors LLC lifted its position in Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after buying an additional 5,232 shares in the last quarter. Quarry LP grew its stake in Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares during the period. nVerses Capital LLC acquired a new stake in shares of Health Catalyst in the third quarter worth $59,000. Finally, Perfromance Wealth Partners LLC purchased a new position in shares of Health Catalyst in the 2nd quarter valued at $64,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HCAT has been the subject of a number of recent analyst reports. Royal Bank of Canada raised their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Citigroup upped their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Evercore ISI boosted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.79.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.